Christopher Hite sold $5.9M of RPRX
EVP & Chairman, Partnering at Royalty Pharma plc. 100,000 shares at an average of $58.53, traded Sep 22, 2026, filed Sep 24, 2026.
Score components
- +20RoleChair
- +25Trade size$5.9M at market
- +10Share of holdings soldSold 27% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001814238-26-000017, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: By SCH Investment Partners LLC10b5-1 | -96,073 | $58.51 | $5.6M | 274,328 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: By SCH Investment Partners LLC10b5-1 | -3,927 | $58.93 | $231k | 270,401 | 18 d ago |
Related signals
Other insiders at Royalty Pharma plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $236k 4,126 shares | -100% | |
| 36Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $239k 4,126 shares | -50% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.